Churchill Capital Corp III (CCXX) Shareholders Approve MultiPlan Deal
by Nicholas Alan Clayton on 2020-10-07 at 2:59pm

Churchill Capital Corp III (CCXX) announced this afternoon that its shareholders had approved its business combination with healthcare data analytics-provider MultiPlan.

About 93% of shareholders representing about 76% of Churchill III’s total outstanding shares voted in favor of the transaction at a special meeting held earlier today.

The two parties expect to close the $11 billion business combination tomorrow and the newly combined entity is expected to begin trading on the NYSE under the symbol “MPLN” Friday, October 9.

Churchill III announced October 6 that as of its redemption deadline it had over $1 billion remaining in its $1.1 billion trust. Much of this was secured in advance as holders of 28,979,500 shares had already agreed not to redeem and owners of 41% of Chruchill III’s total outstanding shares had agreed to vote in favor of the agreement.

The SPAC was required to maintain a minimum of $2.7 billion available as a condition to closing the deal, and it appears to have locked up more than enough in advance with $3.6 billion in capital available at closing.

Recent Posts
by Kristi Marvin on 2024-10-26 at 10:00am

Terms Tracker for the Week Ending October 25, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Finally, a little more SPAC action this week with no less than four IPOs priced.  That brings October’s tally to seven IPOs with one more...

by Nicholas Alan Clayton on 2024-10-25 at 8:15am

At the SPAC of Dawn The rebound of the growth companies that made up the SPAC class of 2021 has been one of the bigger stories of second half of 2024, but not all of the de-SPACs are feeling the love equally. Instead, in many new sectors that hit the public markets together as a...

by Nicholas Alan Clayton on 2024-10-24 at 11:54am

DT Cloud (NASDAQ:DYCQ) has entered into a definitive agreement to combine with Maius Pharmaceutical at an equity value of $250 million. Shanghai-based Maius is a drug developer and researcher focused on small-molecule chemical treatments for different forms of cancer. The combined company is expected to trade on the Nasdaq once the deal is completed in...

by Nicholas Alan Clayton on 2024-10-24 at 10:18am

Charlton Aria Acquisition Corporation announced the pricing of its $75 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “CHARU”, Thursday, October 24, 2024. The new SPAC plans to focus on industries that complement the management team’s and board of director’s background and network. The sponsor team for...

by Nicholas Alan Clayton on 2024-10-24 at 8:30am

At the SPAC of Dawn As the market goes through a cooling period this week, new readouts for jobless claims and new home sales are set to hit later today. Jobless claims are of course something of a proxy indicator for SPACs as to when the Fed might continue to its rate-cutting process, while home...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved